Added 1 day ago Drug news
BMS + Acceleron Pharma provide update on FDA advisory committee for Reblozyl to treat myelodysplastic syndromes.
Bristol-Myers Squibb Company and Acceleron Pharma Inc. announced that following the late-cycle review meeting on 4 December 2019, they were...
Added 4 days ago Drug news
BMS + Acceleron announced that an FDA advisory committee will review Reblozyl for use in patients With myelodysplastic syndromes.
Bristol-Myers Squibb Company and Acceleron Pharma Inc. announced the FDA Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers...
Added 1 month ago Drug news
Amgen announced that the FDA has approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate (romiplostim) to include new data...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...
Added 4 years ago
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Adult soft tissue and visceral sarcomas (excluding gastrointestinal stromal tumor, GIST) are rare tumors, with an estimated incidence averaging 4–5/100 000/year in Europe.
Added 5 years ago
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis...
Added 5 years ago
Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an allogeneic hematopoietic stem cell transplant (HSCT)...
Added 7 months ago
Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.
Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade...
Added 8 months ago
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.
The aim of the present retrospective study is to build a comprehensive picture of all alternative REG strategies adopted in daily clinical practice for use in metastatic GIST patients.
Added 1 year ago
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to IPSS-R very low, low, or intermediate MDS...
Added 1 year ago